Meeting
2015 ASCO Annual Meeting
Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial.
Authors
Bogdana Suchorska
Department of Neurosurgery LMU, Munich, Germany
Bogdana Suchorska , Michael Weller , Ghazaleh Tabatabai , Christian Senft , Peter Hau , Michael Sabel , Ulrich Herrlinger , Ralf Ketter , Uwe S. Schlegel , Christine Marosi , Guido Reifenberger , Wolfgang Wick , Joerg Tonn , Hans-Georg Wirsching
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2041)
DOI
10.1200/jco.2015.33.15_suppl.2041
Abstract #
2041
Poster Bd #
30
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Association of peripheral blood CD4+ T-cell depletion under temozolomide with inferior survival of patients with IDH wildtype glioblastoma.
First Author: Michael Weller
Poster
2013 ASCO Annual Meeting
Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).
First Author: Ghazaleh Tabatabai
Poster
2013 ASCO Annual Meeting
Efficacy and safety of radiotherapy (RT) plus temozolomide (TMZ) in elderly patients (EP) with glioblastoma (GBM).
First Author: Giuseppe Lombardi
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland